APA

Beck J., Schwarzer A., Gläser D., Mügge L., Uhlig J., Heyn S., Kragl B., Mohren M., Hoffmann F. A., Lange T., Schliwa T., Zehrfeld T., Becker C., Kreibich U., Winkelmann C., Edelmann T., Andrea M., Bill M., Jentzsch M., Schwind S., Niederwieser D. & Pönisch W. (20171127). Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). : Journal of cancer research and clinical oncology.

Chicago

Beck Juliane, Schwarzer Andreas, Gläser Dietrich, Mügge Lars-Olof, Uhlig Jens, Heyn Simone, Kragl Brigitte, Mohren Martin, Hoffmann Franz Albert, Lange Thoralf, Schliwa Thomas, Zehrfeld Thomas, Becker Cornelia, Kreibich Ute, Winkelmann Cornelia, Edelmann Thomas, Andrea Marc, Bill Marius, Jentzsch Madlen, Schwind Sebastian, Niederwieser Dietger and Pönisch Wolfram. 20171127. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). : Journal of cancer research and clinical oncology.

Harvard

Beck J., Schwarzer A., Gläser D., Mügge L., Uhlig J., Heyn S., Kragl B., Mohren M., Hoffmann F. A., Lange T., Schliwa T., Zehrfeld T., Becker C., Kreibich U., Winkelmann C., Edelmann T., Andrea M., Bill M., Jentzsch M., Schwind S., Niederwieser D. and Pönisch W. (20171127). Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). : Journal of cancer research and clinical oncology.

MLA

Beck Juliane, Schwarzer Andreas, Gläser Dietrich, Mügge Lars-Olof, Uhlig Jens, Heyn Simone, Kragl Brigitte, Mohren Martin, Hoffmann Franz Albert, Lange Thoralf, Schliwa Thomas, Zehrfeld Thomas, Becker Cornelia, Kreibich Ute, Winkelmann Cornelia, Edelmann Thomas, Andrea Marc, Bill Marius, Jentzsch Madlen, Schwind Sebastian, Niederwieser Dietger and Pönisch Wolfram. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). : Journal of cancer research and clinical oncology. 20171127.